Stem Pharm
PrivateLast Round
Grant
Feb 3, 2026
Total Funding Raised
$4.46M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Stem Pharm operates in Healthcare & Life Sciences and is based in Madison, Wisconsin. Its latest recorded funding round was a Grant round in February 2026.
Stem Pharm is a biotechnology company that has developed a drug discovery platform intended to focus on diseases related to inflammation in the brain.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Advanced Materials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stem Pharm Comparables
Compare Stem Pharm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 28bio | 89% | |
| BrainXell | 85% | |
| OrganoTherapeutics SARL | 85% |
For institutional investors. Book with your work email.
Stem Pharm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 3, 2026 | ||||
| Grant | Sep 1, 2023 | ||||
| Grant | Aug 10, 2023 | ||||
| Accelerator | Dec 20, 2022 | ||||
| Grant | Mar 17, 2021 | ||||
Grant | Aug 12, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Stem Pharm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Merck Global Health Innovation Fund | Accelerator |
| National Cancer Institute | Grant |
| Wisconsin Economic Development Corporation | Grant |
| Northpond Ventures | Accelerator |
| McKesson Ventures | Accelerator |
| National Institute on Aging | Grant |
| National Institute of Environmental Health Sciences | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 57% MoM, reaching 2.2K.
- Jun 17, 2026
Monthly visitors grew 68% MoM, reaching 1.4K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 18, 2026
Stem Pharm, Inc. receives a $2.5M Phase II Small Business Innovation Research grant from the National Institute on Aging, part of the NIH, in Sep '26 to advance its human neuroimmune organoid technology into therapeutic screening.
For institutional investors. Book with your work email.
Stem Pharm Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Stem Pharm's valuation, stock price, and market status.
Is Stem Pharm a public or private company?
Stem Pharm is a private company.
What is the current stock price of Stem Pharm?
Stem Pharm is a private company, so its shares have no public market price. Caplight tracks Stem Pharm's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Stem Pharm worth (valuation)?
Valuation information for Stem Pharm is not publicly available.
Can I buy Stem Pharm stock?
Stem Pharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Stem Pharm's last funding round?
Stem Pharm's most recent funding round was Grant on February 3, 2026.
Who are the main investors in Stem Pharm?
Key investors in Stem Pharm include Merck Global Health Innovation Fund, Illumina Accelerator.
Will Stem Pharm IPO soon?
No public IPO plans have been announced for Stem Pharm.
How can I track Stem Pharm secondary market activity?
Caplight tracks bids, offers, and trades in Stem Pharm's shares on secondary markets.